FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML)

Por J.E. Lancet, T.L. Lin, D. Hogge, S.R. Solomon, G.J. Schiller, M.J. Wieduwilt, R. Martin, S. Faderl, Y. Chang, J.E. Cortes
Publicado em 2020-11-01